Castle Biosciences' Gross Profit fell 831.37% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.6 million, marking a year-over-year increase of 751.7%. This contributed to the annual value of $271.9 million for FY2024, which is 5552.33% up from last year.
Per Castle Biosciences' latest filing, its Gross Profit stood at $64.3 million for Q3 2025, which was down 831.37% from $68.6 million recorded in Q2 2025.
In the past 5 years, Castle Biosciences' Gross Profit registered a high of $72.5 million during Q2 2024, and its lowest value of $19.0 million during Q3 2021.
Moreover, its 5-year median value for Gross Profit was $39.1 million (2023), whereas its average is $43.9 million.
Its Gross Profit has fluctuated over the past 5 years, first soared by 8633.15% in 2023, then plummeted by 831.37% in 2025.
Quarter analysis of 5 years shows Castle Biosciences' Gross Profit stood at $20.4 million in 2021, then soared by 40.97% to $28.8 million in 2022, then skyrocketed by 86.33% to $53.7 million in 2023, then soared by 30.6% to $70.1 million in 2024, then fell by 8.25% to $64.3 million in 2025.
Its Gross Profit was $64.3 million in Q3 2025, compared to $68.6 million in Q2 2025 and $71.6 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value